Skip to content
Clinical Trials – home
EstoniaBack to Estonia

Clinical trials in Nomme Linnaosa

159 clinical trials in Nomme Linnaosa, Estonia. Every trial is listed in the EU Clinical Trials Register and updated daily.

EstoniaOur site in EstoniaKliinilisedUuringud.ee(opens in a new tab)
Nomme Linnaosa at a glance
159
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

159 trials in Nomme Linnaosa

Open in trial search

Phase 2b Study of VXB-221 and VXB-213 Protein Vaccine for Prevention of Respiratory Syncytial Virus and Human Metapneumovirus Infections in Adults ≥60 Years

Investigational
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:VXB-213
  • Sponsor:Sanofi Pasteur Inc.

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Investigational
Countries:EstoniaEstonia
  • Participants:18–64 years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Efficacy and safety of efgartigimod alfa in adults with Sjögren’s disease‑associated sensorimotor or sensory polyneuropathy: a phase 2 randomized placebo‑controlled study

Registered drug
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

Investigational
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

A Study Comparing Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

Registered drug
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Crohn's disease

Recruiting

Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn's Disease

Investigational
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:MORF-057
  • Sponsor:Morphic Therapeutic Inc.

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational
Countries:EstoniaEstonia
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Other cities in Estonia

The busiest research cities in the country

All 10 cities in Estonia

Clinical research in Nomme Linnaosa

What the registry says about research in the country

01 Rheumatology Research

Innovative clinical studies focusing on psoriatic arthritis treatments are evaluating long-term therapeutic solutions. The research aims to assess extended safety profiles and measure treatment effectiveness using standardized American College of Rheumatology response criteria.

  • Long-term safety assessment
  • Treatment efficacy evaluation
  • Extended patient monitoring

These trials represent significant advancement in understanding chronic inflammatory joint conditions.

02 Gastroenterology Studies

Current research initiatives are exploring new therapeutic approaches for patients with ulcerative colitis. Clinical investigations are specifically targeting moderate to severe cases, with a focus on achieving clinical remission through innovative treatment methods.

  • Clinical remission assessment
  • Inflammatory bowel disease management
  • Novel therapeutic evaluation

This research aims to expand treatment options for patients with inflammatory bowel conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.